THE QUALITY OF LIFE OF ANEMIC PATIENTS WITH LYMPHOPROLIFERATIVE DISORDERS TREATED WITH RED BLOOD CELL TRANSFUSIONS AND ERYTHROPOIESIS-STIMULATING AGENTS
(Abstract release date: 05/21/15)
EHA Library. Romanenko N. 06/12/15; 102598; PB1976
Disclosure(s): Russian Research Institute of Hematology and Transfusiology, FMBA of RussiaClinical Hematology
Mr. Nikolay Romanenko
Contributions
Contributions
Abstract
Abstract: PB1976
Type: Publication Only
Background
Aims
Methods
There were included 131 anemic patients with LPD (multiple myeloma, low-grade non-Hodgkin's lymphoma, chronic lymphocytic leukemia). Median age of patients was 67 years (range 24-85). All persons were divided into two groups: 1st group included patients (n=54) treated with RBCsT, 2nd (n=77) – treated with ESA. Posetive response for ESA considered as achievement of hemoglobine concentration 120 g/L or increase Hb ≥ 20 g/L. QoL was studied with Functional Assessment of Cancer Therapy Anemia subscale (FACT-An) and Fatigue subscale (FACT-F).
Results
In the 1st group of patients treated with RBCsT (in average 3.7±0.3 Units) concentration of Hb increased from 70.0±1.6 g/L to 93.1±1.2 g/L. Statistically significant improvement of their QoL was found in FACT-An subscale – from 41.1±2.0 (95% Cl=37.1-45.0) to 34.2±2.1 (95% Cl=30.0-38.3) points (p<0.001; n=54). Improvement of QoL was also found in FACT-F subscale – from 30.2±1.4 (95% Cl=27.8-32.9) to 23.2±1.5 (95% Cl=19.8-26.9) points (p<0.0001; n=54). In the 2nd group positive response for ESA-therapy was found in 52 (67.5%) out of 77 patients: 39 (50.6%) patients achieved the Hb concentration 120 g/L and 13 (16.9%) ones increased Hb more than 20 g/L. The patients with positive response increased the Hb concentration significantly from 88.4±1.4 g/L to 123.1±2.4 g/L (p<0.0001; n=52). We found out improvement of QoL in both subscale: in FACT-An – from 34.5±1.7 (95% Cl=31.1-37.9) to 30.1±1.6 (95% Cl=26.9-33.2) points (p<0.001; n=52) and in FACT-F – from 22.8±1.3 (95% Cl=20.3-25.4) to 19.7±1.2 (95% Cl=17.3-22.1) points (p=0.013; n=52).
Summary
Both RBCsT and ESA-therapy are able to increase Hb concentration considerably and improve QoL. However the RBCsT patients had more severe anemia and over a period of its correction the RBCsT patients’s planned level of Hb was less than ESA-patietnts’s one therefore their final QoL was less. So using the ESA-therapy can increase higher Hb concentration and improve QoL more than RBCsT. It’s indicating importance of ESA-therapy not as alternative RBCsT method of anemia’s correction but also as a way to prevent decreasing of the Hb induced by toxic effect of chemotherapy and as a method of anemia treatment with which a normal Hb level can be achieved.
Keyword(s): Anemia, Erythropoietin, Lymphoproliferative disorder, Transfusion
Type: Publication Only
Background
Although haematological toxicities, such as anemia, are common in lymphoproliferative disorders (LPD), no clear consensus exists on the use and impact of Erythropoiesis-stimulating agents (ESA) and Red blood cells transfusions (RBCsT) on quality of life (QoL).
Aims
To assess alteration of QoL in anemic patients with LPD treated with RBCsT and ESA.
Methods
There were included 131 anemic patients with LPD (multiple myeloma, low-grade non-Hodgkin's lymphoma, chronic lymphocytic leukemia). Median age of patients was 67 years (range 24-85). All persons were divided into two groups: 1st group included patients (n=54) treated with RBCsT, 2nd (n=77) – treated with ESA. Posetive response for ESA considered as achievement of hemoglobine concentration 120 g/L or increase Hb ≥ 20 g/L. QoL was studied with Functional Assessment of Cancer Therapy Anemia subscale (FACT-An) and Fatigue subscale (FACT-F).
Results
In the 1st group of patients treated with RBCsT (in average 3.7±0.3 Units) concentration of Hb increased from 70.0±1.6 g/L to 93.1±1.2 g/L. Statistically significant improvement of their QoL was found in FACT-An subscale – from 41.1±2.0 (95% Cl=37.1-45.0) to 34.2±2.1 (95% Cl=30.0-38.3) points (p<0.001; n=54). Improvement of QoL was also found in FACT-F subscale – from 30.2±1.4 (95% Cl=27.8-32.9) to 23.2±1.5 (95% Cl=19.8-26.9) points (p<0.0001; n=54). In the 2nd group positive response for ESA-therapy was found in 52 (67.5%) out of 77 patients: 39 (50.6%) patients achieved the Hb concentration 120 g/L and 13 (16.9%) ones increased Hb more than 20 g/L. The patients with positive response increased the Hb concentration significantly from 88.4±1.4 g/L to 123.1±2.4 g/L (p<0.0001; n=52). We found out improvement of QoL in both subscale: in FACT-An – from 34.5±1.7 (95% Cl=31.1-37.9) to 30.1±1.6 (95% Cl=26.9-33.2) points (p<0.001; n=52) and in FACT-F – from 22.8±1.3 (95% Cl=20.3-25.4) to 19.7±1.2 (95% Cl=17.3-22.1) points (p=0.013; n=52).
Summary
Both RBCsT and ESA-therapy are able to increase Hb concentration considerably and improve QoL. However the RBCsT patients had more severe anemia and over a period of its correction the RBCsT patients’s planned level of Hb was less than ESA-patietnts’s one therefore their final QoL was less. So using the ESA-therapy can increase higher Hb concentration and improve QoL more than RBCsT. It’s indicating importance of ESA-therapy not as alternative RBCsT method of anemia’s correction but also as a way to prevent decreasing of the Hb induced by toxic effect of chemotherapy and as a method of anemia treatment with which a normal Hb level can be achieved.
Keyword(s): Anemia, Erythropoietin, Lymphoproliferative disorder, Transfusion
Abstract: PB1976
Type: Publication Only
Background
Aims
Methods
There were included 131 anemic patients with LPD (multiple myeloma, low-grade non-Hodgkin's lymphoma, chronic lymphocytic leukemia). Median age of patients was 67 years (range 24-85). All persons were divided into two groups: 1st group included patients (n=54) treated with RBCsT, 2nd (n=77) – treated with ESA. Posetive response for ESA considered as achievement of hemoglobine concentration 120 g/L or increase Hb ≥ 20 g/L. QoL was studied with Functional Assessment of Cancer Therapy Anemia subscale (FACT-An) and Fatigue subscale (FACT-F).
Results
In the 1st group of patients treated with RBCsT (in average 3.7±0.3 Units) concentration of Hb increased from 70.0±1.6 g/L to 93.1±1.2 g/L. Statistically significant improvement of their QoL was found in FACT-An subscale – from 41.1±2.0 (95% Cl=37.1-45.0) to 34.2±2.1 (95% Cl=30.0-38.3) points (p<0.001; n=54). Improvement of QoL was also found in FACT-F subscale – from 30.2±1.4 (95% Cl=27.8-32.9) to 23.2±1.5 (95% Cl=19.8-26.9) points (p<0.0001; n=54). In the 2nd group positive response for ESA-therapy was found in 52 (67.5%) out of 77 patients: 39 (50.6%) patients achieved the Hb concentration 120 g/L and 13 (16.9%) ones increased Hb more than 20 g/L. The patients with positive response increased the Hb concentration significantly from 88.4±1.4 g/L to 123.1±2.4 g/L (p<0.0001; n=52). We found out improvement of QoL in both subscale: in FACT-An – from 34.5±1.7 (95% Cl=31.1-37.9) to 30.1±1.6 (95% Cl=26.9-33.2) points (p<0.001; n=52) and in FACT-F – from 22.8±1.3 (95% Cl=20.3-25.4) to 19.7±1.2 (95% Cl=17.3-22.1) points (p=0.013; n=52).
Summary
Both RBCsT and ESA-therapy are able to increase Hb concentration considerably and improve QoL. However the RBCsT patients had more severe anemia and over a period of its correction the RBCsT patients’s planned level of Hb was less than ESA-patietnts’s one therefore their final QoL was less. So using the ESA-therapy can increase higher Hb concentration and improve QoL more than RBCsT. It’s indicating importance of ESA-therapy not as alternative RBCsT method of anemia’s correction but also as a way to prevent decreasing of the Hb induced by toxic effect of chemotherapy and as a method of anemia treatment with which a normal Hb level can be achieved.
Keyword(s): Anemia, Erythropoietin, Lymphoproliferative disorder, Transfusion
Type: Publication Only
Background
Although haematological toxicities, such as anemia, are common in lymphoproliferative disorders (LPD), no clear consensus exists on the use and impact of Erythropoiesis-stimulating agents (ESA) and Red blood cells transfusions (RBCsT) on quality of life (QoL).
Aims
To assess alteration of QoL in anemic patients with LPD treated with RBCsT and ESA.
Methods
There were included 131 anemic patients with LPD (multiple myeloma, low-grade non-Hodgkin's lymphoma, chronic lymphocytic leukemia). Median age of patients was 67 years (range 24-85). All persons were divided into two groups: 1st group included patients (n=54) treated with RBCsT, 2nd (n=77) – treated with ESA. Posetive response for ESA considered as achievement of hemoglobine concentration 120 g/L or increase Hb ≥ 20 g/L. QoL was studied with Functional Assessment of Cancer Therapy Anemia subscale (FACT-An) and Fatigue subscale (FACT-F).
Results
In the 1st group of patients treated with RBCsT (in average 3.7±0.3 Units) concentration of Hb increased from 70.0±1.6 g/L to 93.1±1.2 g/L. Statistically significant improvement of their QoL was found in FACT-An subscale – from 41.1±2.0 (95% Cl=37.1-45.0) to 34.2±2.1 (95% Cl=30.0-38.3) points (p<0.001; n=54). Improvement of QoL was also found in FACT-F subscale – from 30.2±1.4 (95% Cl=27.8-32.9) to 23.2±1.5 (95% Cl=19.8-26.9) points (p<0.0001; n=54). In the 2nd group positive response for ESA-therapy was found in 52 (67.5%) out of 77 patients: 39 (50.6%) patients achieved the Hb concentration 120 g/L and 13 (16.9%) ones increased Hb more than 20 g/L. The patients with positive response increased the Hb concentration significantly from 88.4±1.4 g/L to 123.1±2.4 g/L (p<0.0001; n=52). We found out improvement of QoL in both subscale: in FACT-An – from 34.5±1.7 (95% Cl=31.1-37.9) to 30.1±1.6 (95% Cl=26.9-33.2) points (p<0.001; n=52) and in FACT-F – from 22.8±1.3 (95% Cl=20.3-25.4) to 19.7±1.2 (95% Cl=17.3-22.1) points (p=0.013; n=52).
Summary
Both RBCsT and ESA-therapy are able to increase Hb concentration considerably and improve QoL. However the RBCsT patients had more severe anemia and over a period of its correction the RBCsT patients’s planned level of Hb was less than ESA-patietnts’s one therefore their final QoL was less. So using the ESA-therapy can increase higher Hb concentration and improve QoL more than RBCsT. It’s indicating importance of ESA-therapy not as alternative RBCsT method of anemia’s correction but also as a way to prevent decreasing of the Hb induced by toxic effect of chemotherapy and as a method of anemia treatment with which a normal Hb level can be achieved.
Keyword(s): Anemia, Erythropoietin, Lymphoproliferative disorder, Transfusion
{{ help_message }}
{{filter}}